Search

Your search keyword '"Edil, Barish H."' showing total 667 results
Start Over Author "Edil, Barish H."
667 results on '"Edil, Barish H."'

1. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

Author

Murthy, Divya, Attri, Kuldeep S., Shukla, Surendra K., Thakur, Ravi, Chaika, Nina V., He, Chunbo, Wang, Dezhen, Jha, Kanupriya, Dasgupta, Aneesha, King, Ryan J., Mulder, Scott E., Souchek, Joshua, Gebregiworgis, Teklab, Rai, Vikant, Patel, Rohit, Hu, Tuo, Rana, Sandeep, Kollala, Sai Sundeep, Pacheco, Camila, Grandgenett, Paul M., Yu, Fang, Kumar, Vikas, Lazenby, Audrey J., Black, Adrian R., Ulhannan, Susanna, Jain, Ajay, Edil, Barish H., Klinkebiel, David L., Powers, Robert, Natarajan, Amarnath, Hollingsworth, Michael A., Mehla, Kamiya, Ly, Quan, Chaudhary, Sarika, Hwang, Rosa F., Wellen, Kathryn E., and Singh, Pankaj K.

Published
2024
Full Text
View/download PDF

3. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

Author

Murthy, Divya, Attri, Kuldeep S., Shukla, Surendra K., Thakur, Ravi, Chaika, Nina V., He, Chunbo, Wang, Dezhen, Jha, Kanupriya, Dasgupta, Aneesha, King, Ryan J., Mulder, Scott E., Souchek, Joshua, Gebregiworgis, Teklab, Rai, Vikant, Patel, Rohit, Hu, Tuo, Rana, Sandeep, Kollala, Sai Sundeep, Pacheco, Camila, Grandgenett, Paul M., Yu, Fang, Kumar, Vikas, Lazenby, Audrey J., Black, Adrian R., Ulhannan, Susanna, Jain, Ajay, Edil, Barish H., Klinkebiel, David L., Powers, Robert, Natarajan, Amarnath, Hollingsworth, Michael A., Mehla, Kamiya, Ly, Quan, Chaudhary, Sarika, Hwang, Rosa F., Wellen, Kathryn E., and Singh, Pankaj K.

Published
2024
Full Text
View/download PDF

5. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy

Author

Sun, Yi, Chen, Wei, Torphy, Robert J, Yao, Sheng, Zhu, Gefeng, Lin, Ronggui, Lugano, Roberta, Miller, Emily N, Fujiwara, Yuki, Bian, Li, Zheng, Linghua, Anand, Sudarshan, Gao, Fan, Zhang, Weizhou, Ferrara, Sarah E, Goodspeed, Andrew E, Dimberg, Anna, Wang, Xiao-Jing, Edil, Barish H, Barnett, Carlton C, Schulick, Richard D, Chen, Lieping, and Zhu, Yuwen

Subjects
Biotechnology, Cancer, Vaccine Related, Immunization, 2.1 Biological and endogenous factors, Aetiology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Animals, Endothelial Cells, Humans, Immunotherapy, Mice, Neoplasms, Pharmaceutical Preparations, Tumor Microenvironment, Biological Sciences, Medical and Health Sciences
Abstract

The immature and dysfunctional vascular network within solid tumors poses a substantial obstacle to immunotherapy because it creates a hypoxic tumor microenvironment that actively limits immune cell infiltration. The molecular basis underpinning this vascular dysfunction is not fully understood. Using genome-scale receptor array technology, we showed here that insulin-like growth factor binding protein 7 (IGFBP7) interacts with its receptor CD93, and we subsequently demonstrated that this interaction contributes to abnormal tumor vasculature. Both CD93 and IGFBP7 were up-regulated in tumor-associated endothelial cells. IGFBP7 interacted with CD93 via a domain different from multimerin-2, the known ligand for CD93. In two mouse tumor models, blockade of the CD93/IGFBP7 interaction by monoclonal antibodies promoted vascular maturation to reduce leakage, leading to reduced tumor hypoxia and increased tumor perfusion. CD93 blockade in mice increased drug delivery, resulting in an improved antitumor response to gemcitabine or fluorouracil. Blockade of the CD93 pathway triggered a substantial increase in intratumoral effector T cells, thereby sensitizing mouse tumors to immune checkpoint therapy. Last, analysis of samples from patients with cancer under anti-programmed death 1/programmed death-ligand 1 treatment revealed that overexpression of the IGFBP7/CD93 pathway was associated with poor response to therapy. Thus, our study identified a molecular interaction involved in tumor vascular dysfunction and revealed an approach to promote a favorable tumor microenvironment for therapeutic intervention.

Published
2021

8. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2.

Author

Hatoum, Hassan, Rosemurgy, Alexander, Bastidas, J Augusto, Zervos, Emmanuel, Muscarella, Peter, Edil, Barish H, Cynamon, Jacob, Johnson, D Thor, Thomas, Christopher, Swinson, Bradley M, Nordgren, Aaron, Vitulli, Paul, Nutting, Charles, Gipson, Matthew, Tsobanoudis, Alex, and Agah, Ramtin

Subjects
PATIENT safety, RESEARCH funding, CLINICAL trials, CHEMORADIOTHERAPY, DESCRIPTIVE statistics, PANCREATIC tumors, CANCER chemotherapy, GEMCITABINE, DRUG efficacy, PERFUSION, CONFIDENCE intervals, OVERALL survival
Abstract

Background Locally advanced pancreatic cancer (LAPC) comprises 40% of pancreatic cancer diagnoses and has a relatively poor prognosis. Trans-arterial micro perfusion (TAMP)-mediated chemotherapy delivery to the primary tumor is a novel approach worthy of investigation. The RR1 (dose escalation) and RR2 (observational) studies examined the safety and preliminary efficacy of TAMP-delivered gemcitabine for LAPC. Patients and Methods RR1 and RR2 data were pooled. Both studies enrolled patients with LAPC with histologically confirmed adenocarcinoma. Participant data, including age, sex, race, stage, previous treatments, toxicity, disease progression, and death, were collected. Median number of cycles and average treatment dosage were calculated. Overall survival (OS) was determined for the whole group and separately for patients who received and did not receive previous treatments. Aims of the analysis were to assess procedure safety, OS, and evaluate factors associated with OS. Results The median age of the 43 patients enrolled in RR1 and RR2 was 72 years (range, 51-88 years). Median OS for the 35 eligible patients with stage III disease was 12.6 months (95% CI, 2.1-54.2 months). Previous chemoradiation was associated with significantly longer OS [27.1 months (95% CI, 8.4-40.6 months)] compared to previous systemic chemotherapy [14.6 months (95% CI, 6.4-54.2 months)] or no prior treatment [7.0 months (95% CI, 2.1-35.4 months)] (P  < .001). The most common adverse events were GI related (abdominal pain, emesis, and vomiting); the most common grade 3 toxicity was sepsis. Conclusion Study results indicate that TAMP-mediated gemcitabine delivery in patients with LAPC is potentially safe, feasible, and provides potential clinical benefits. Clinical Trial Registration NCT02237157 (RR1) and NCT02591082 (RR2). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells

Author

Liu, Mingyang, Zhang, Yuqing, Yang, Jingxuan, Cui, Xiaobo, Zhou, Zhijun, Zhan, Hanxiang, Ding, Kai, Tian, Xiang, Yang, Zhibo, Fung, Kar-Ming A., Edil, Barish H., Postier, Russell G., Bronze, Michael S., Fernandez-Zapico, Martin E., Stemmler, Marc P., Brabletz, Thomas, Li, Yi-Ping, Houchen, Courtney W., and Li, Min

Published
2020
Full Text
View/download PDF

12. ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells

Author

Yang, Jingxuan, Zhang, Zicheng, Zhang, Yuqing, Ni, Xiaoling, Zhang, Guohua, Cui, Xiaobo, Liu, Mingyang, Xu, Can, Zhang, Qiang, Zhu, Huiyun, Yan, Jie, Zhu, Vivian F., Luo, Yusheng, Hagan, John P., Li, Zhaoshen, Fang, Jing, Jatoi, Aminah, Fernandez-Zapico, Martin E., Zheng, Lei, Edil, Barish H., Bronze, Michael S., Houchen, Courtney W., Li, Yi-Ping, and Li, Min

Published
2019
Full Text
View/download PDF

13. Theranostic nanoparticles for detection and treatment of pancreatic cancer.

Author

Agarwal, Happy, Bynum, Ryan C., Saleh, Nada, Harris, Danielle, MacCuaig, William M., Kim, Vung, Sanderson, Emma J., Dennahy, Isabel S., Singh, Rohit, Behkam, Bahareh, Gomez‐Gutierrez, Jorge G., Jain, Ajay, Edil, Barish H., and McNally, Lacey R.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most recalcitrant cancers due to its late diagnosis, poor therapeutic response, and highly heterogeneous microenvironment. Nanotechnology has the potential to overcome some of the challenges to improve diagnostics and tumor‐specific drug delivery but they have not been plausibly viable in clinical settings. The review focuses on active targeting strategies to enhance pancreatic tumor‐specific uptake for nanoparticles. Additionally, this review highlights using actively targeted liposomes, micelles, gold nanoparticles, silica nanoparticles, and iron oxide nanoparticles to improve pancreatic tumor targeting. Active targeting of nanoparticles toward either differentially expressed receptors or PDAC tumor microenvironment (TME) using peptides, antibodies, small molecules, polysaccharides, and hormones has been presented. We focus on microenvironment‐based hallmarks of PDAC and the potential for actively targeted nanoparticles to overcome the challenges presented in PDAC. It describes the use of nanoparticles as contrast agents for improved diagnosis and the delivery of chemotherapeutic agents that target various aspects within the TME of PDAC. Additionally, we review emerging nano‐contrast agents detected using imaging‐based technologies and the role of nanoparticles in energy‐based treatments of PDAC. This article is categorized under:Implantable Materials and Surgical Technologies > Nanoscale Tools and Techniques in SurgeryTherapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic DiseaseDiagnostic Tools > In Vivo Nanodiagnostics and Imaging [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Intraoperative Imaging in Hepatopancreatobiliary Surgery

Author

Husarova, Tereza, primary, MacCuaig, William M., additional, Dennahy, Isabel S., additional, Sanderson, Emma J., additional, Edil, Barish H., additional, Jain, Ajay, additional, Bonds, Morgan M., additional, McNally, Molly W., additional, Menclova, Katerina, additional, Pudil, Jiri, additional, Zaruba, Pavel, additional, Pohnan, Radek, additional, Henson, Christina E., additional, Grizzle, William E., additional, and McNally, Lacey R., additional

Published
2023
Full Text
View/download PDF

25. The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection

Author

Asbun, Horacio J., Moekotte, Alma L., Vissers, Frederique L., Kunzler, Filipe, Cipriani, Federica, Alseidi, Adnan, D’Angelica, Michael I., Balduzzi, Alberto, Bassi, Claudio, Björnsson, Bergthor, Boggi, Ugo, Callery, Mark P., Del Chiaro, Marco, Coimbra, Felipe J., Conrad, Claudius, Cook, Andrew, Coppola, Alessandro, Dervenis, Christos, Dokmak, Safi, Edil, Barish H., Edwin, Bjørn, Giulianotti, Pier C., Han, Ho-Seong, Hansen, Paul D., van der Heijde, Nicky, van Hilst, Jony, Hester, Caitlin A., Hogg, Melissa E., Jarufe, Nicolas, Jeyarajah, D. Rohan, Keck, Tobias, Kim, Song Cheol, Khatkov, Igor E., Kokudo, Norihiro, Kooby, David A., Korrel, Maarten, de Leon, Francisco J., Lluis, Nuria, Lof, Sanne, Machado, Marcel A., Demartines, Nicolas, Martinie, John B., Merchant, Nipun B., Molenaar, I. Quintus, Moravek, Cassadie, Mou, Yi-Ping, Nakamura, Masafumi, Nealon, William H., Palanivelu, Chinnusamy, Pessaux, Patrick, Pitt, Henry A., Polanco, Patricio M., Primrose, John N., Rawashdeh, Arab, Sanford, Dominic E., Senthilnathan, Palanisamy, Shrikhande, Shailesh V., Stauffer, John A., Takaori, Kyoichi, Talamonti, Mark S., Tang, Chung N., Vollmer, Charles M., Wakabayashi, Go, Walsh, R. Matthew, Wang, Shin-E, Zinner, Michael J., Wolfgang, Christopher L., Zureikat, Amer H., Zwart, Maurice J., Conlon, Kevin C., Kendrick, Michael L., Zeh, Herbert J., Hilal, Mohammad Abu, and Besselink, Marc G.

Published
2020
Full Text
View/download PDF

39. Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study

Author

Gaddam, Srinivas, Ge, Phillip S., Keach, Joseph W., Mullady, Daniel, Fukami, Norio, Edmundowicz, Steven A., Azar, Riad R., Shah, Raj J., Murad, Faris M., Kushnir, Vladimir M., Watson, Rabindra R., Ghassemi, Kourosh F., Sedarat, Alireza, Komanduri, Srinadh, Jaiyeola, Diana-Marie, Brauer, Brian C., Yen, Roy D., Amateau, Stuart K., Hosford, Lindsay, Hollander, Thomas, Donahue, Timothy R., Schulick, Richard D., Edil, Barish H., McCarter, Martin, Gajdos, Csaba, Attwell, Augustin, Muthusamy, V. Raman, Early, Dayna S., and Wani, Sachin

Published
2015
Full Text
View/download PDF

40. A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts

Author

Springer, Simeon, Wang, Yuxuan, Dal Molin, Marco, Masica, David L., Jiao, Yuchen, Kinde, Isaac, Blackford, Amanda, Raman, Siva P., Wolfgang, Christopher L., Tomita, Tyler, Niknafs, Noushin, Douville, Christopher, Ptak, Janine, Dobbyn, Lisa, Allen, Peter J., Klimstra, David S., Schattner, Mark A., Schmidt, C. Max, Yip-Schneider, Michele, Cummings, Oscar W., Brand, Randall E., Zeh, Herbert J., Singhi, Aatur D., Scarpa, Aldo, Salvia, Roberto, Malleo, Giuseppe, Zamboni, Giuseppe, Falconi, Massimo, Jang, Jin-Young, Kim, Sun-Whe, Kwon, Wooil, Hong, Seung-Mo, Song, Ki-Byung, Kim, Song Cheol, Swan, Niall, Murphy, Jean, Geoghegan, Justin, Brugge, William, Fernandez-Del Castillo, Carlos, Mino-Kenudson, Mari, Schulick, Richard, Edil, Barish H., Adsay, Volkan, Paulino, Jorge, van Hooft, Jeanin, Yachida, Shinichi, Nara, Satoshi, Hiraoka, Nobuyoshi, Yamao, Kenji, Hijioka, Susuma, van der Merwe, Schalk, Goggins, Michael, Canto, Marcia Irene, Ahuja, Nita, Hirose, Kenzo, Makary, Martin, Weiss, Matthew J., Cameron, John, Pittman, Meredith, Eshleman, James R., Diaz, Luis A., Jr., Papadopoulos, Nickolas, Kinzler, Kenneth W., Karchin, Rachel, Hruban, Ralph H., Vogelstein, Bert, and Lennon, Anne Marie

Published
2015
Full Text
View/download PDF

49. Launch of the PANC-PALS Consortium

Author

Javed, Ammar A, Hidalgo Salinas, Camila, Wolfgang, Christopher L, Besselink, Marc G, Ahmad, Syed A., Ahuja, Nita, Andel, Paul C.M., Asbun, Horacio J., Bauer, Todd W., Boggi, Ugo, Bonsing, Bert A., Büchler, Markus W., Butturini, Giovanni, Busch, Oliver R., Cobos, Stanley, Daamen, Lois A., Dameseviciute, Ryte, Datta, Jashodeep, Dervenis, Christos, Diener, Markus K., Dixon, Elijah, Donahue, Timothy R., Edil, Barish H., Ejaz, Aslam, Falconi, Massimo, Lavista Ferres, Juan M, Ferrone, Cristina R., Fong, Zhi V., Fusai, Giuseppe K., Garnier, Jonathan, Groot Koerkamp, Bas, Hansen, Carsten P., Habib, Joseph R., Hashimoto, Daisuke, He, Jin, Hingh, Ignace H.J.T., Inoue, Yosuke, Islam, Saleem, Jang, Jin-Young, Jiang, Kuirong, Katz, Matthew H., Kooby, David A., Lancaster, William P., Maker, Ajay V., Marchegiani, Giovanni, Marchetti, Alessio, Matsumoto, Ippei, McGinty, Patricia A., Molenaar, I. Quintus, Nagakawa, Yuichi, Page, Andrew J., Poultsides, George A., Qadan, Motaz, Rangelova, Elena, Reames, Bradley N., Reddy, Sushanth, Roberts, Keith J., Rocha, Flavio G., Rompen, Ingmar F., Sacks, Greg D., de Santibanes, Martin, Schwartz, Myron E., Seppänen, Hanna, Sham, Jonathan G., Shrikhande, Shailesh, Smith, Andrew, Sparrelid, Ernesto, Stoop, Thomas F., Tingstedt, Bobby, Truty, Mark J., Uhl, Waldemar, Weiss, Matthew J., Werner, Jens, Winter, Jordan M., Zafar, Syed Nabeel, Zeh, Herbert J., Zerbi, Alessandro, Zhao, Yupei, and Zyromski, Nicholas J.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results